Project 2: COS-ILCCO
Combining data from around the world will help in our understanding of lung cancer biology, epidemiology, and outcomes. To understand lung cancer biology and improve clinical outcomes, we must understand similarities and differences in lung cancer epidemiology, demographics, treatments and outcomes across the world.
How are lung cancer outcomes similar or different worldwide?
Summary:Since 2016, The Princess Margaret has been the coordinating centre for the large lung cancer consortium, COS-ILCCO, an extension of ILCCO which we have been involved in for over a decade. While ILCCO focused on identifying genetic factors for the risk of lung cancer, COS-ILCCO is focused on the role of clinical and genetic factors in the outcomes of lung cancer.
The laboratory recently combined data from over 55,000 lung cancer cases from multiple continents in order to study the factors associated better or worse outcomes in lung cancer. These large numbers across different ethnicities will help us understand geographic, socio-cultural, and ethnic differences in lung cancer outcomes.
(1) To evaluate the role of clinical factors in the outcomes of lung cancer worldwide, by important subgroups such as stage and histology; and
(2) To evaluate the role of genetic germline factors, and their interaction with biological, clinico-demographic, epidemiological, molecular and behavioural factors, on clinical outcomes.
Funding Sources: Alan Brown Chair in Molecular Genomics; Visiting Scientist funding from People’s Republic of China; Fellowship funding from Israel.